 | | Vol. 13.11 – 25 March, 2022 |
| |
|
|
| miR-346 could be particularly effective as a therapeutic in the context of decreased NORAD observed in advanced prostate cancer, and in transcriptionally-hyperactive cancer cells.
[Molecular Cancer] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Comprehensive mapping of the mTOR chromatin-bound interactome in both androgen-dependent and -independent cellular models of prostate cancer identified a conserved 67-protein interaction network enriched for chromatin modifiers, transcription factors, and SUMOylation machinery.
[Cell Reports] |
|
|
|
| Scientists detected that the loss of the androgen-responsive transcription factor, zinc finger, and BTB domain containing 10 (ZBTB10), could activate pyruvate kinase L/R to enhance a neuroendocrine differentiation response that was associated with glucose uptake by prostate cancer cells.
[Cell Death & Disease] |
|
|
|
| Researchers reported that autophagy affected differently the response of prostate cancer cell lines to olaparib depending on its activation status.
[Communications Biology] |
|
|
|
| In vitro and in vivo data provided new insights for understanding the mechanisms underlying high-dose-dihydrotestosterone suppression of the enzalutamide-resistant CRPC cell growth, supporting a potential therapy using high-dose-androgens to suppress CRPC progression in the future.
[Cell Death Discovery] |
|
|
|
| The authors assessed the function of KMT2C in prostate cancer cell proliferation, colony formation, and migration.
[Journal of Cancer Research and Clinical Oncology] |
|
|
|
| Researchers investigated the use of designed ankyrin repeat protein Ec1 for targeted delivery of Pseudomonas exotoxin A variant (LoPE) with low immunogenicity and low non‑specific toxicity to epithelial cell adhesion molecule‑expressing prostate cancer cells.
[Oncology Reports] |
|
|
|
| Investigators analyzed the carcinogenetic potential of exposure to GHRH of a nontumor human prostate epithelial cell line (RWPE-1) as well as its transforming effect in a xenograft model.
[Prostate] |
|
|
|
| Through co-targeting the androgen receptor (AR) signaling, Diptoindonesin G robustly improved the efficacy of HSP90 inhibitors and enzalutamide in both human prostate cancer cells and in vivo xenograft mouse model.
[Prostate] |
|
|
|
| Scientists investigated whether the novel factor 3,5-dihydroxy-4-methoxybenzyl alcohol suppressed the activity of metastatic human prostate cancer PC-3 or DU-145 cells.
[Anti-Cancer Drugs] |
|  |
|
|
|
| The authors provide a mechanistic discussion of autophagy in prostate cancer.
[Journal of Experimental & Clinical Cancer Research] |
|
|
|
| Scientists discuss the advancement of PCSK9 research on its role and underlying mechanisms in tumor development and progression.
[Naunyn-Schmiedebergs Archives of Pharmacology] |
|
|
|
|
| Novartis announced today that the US FDA approved PluvictoTM for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen–positive metastatic CRPC that has spread to other parts of the body.
[Novartis Pharma AG] |
|
|
|
|
| May 25 – 29, 2022
Lyon, France |
|
|
|
|
|
| | CRUK Manchester Institute – Manchester, United Kingdom |
|
|
|
| | University of Southern Denmark – Odense M, Denmark |
|
|
|
| | Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
| | The University of British Columbia – Vancouver, British Columbia, Canada |
|
|
|
| | Singapore-MIT Alliance for Research and Technology (SMART) Centre – Singapore, Singapore |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
